Create your very own Auto Publish News/Blog Site and Earn Passive Income in Just 4 Easy Steps
Mark Baum is a prominent figure in the business world, known for his success as the Chief Executive Officer and Director of Harrow Health. Many are curious about his net worth and financial achievements. Let’s delve into the details and uncover just how much Mark Baum is worth.
Key Takeaways:
- Mark Baum has an estimated net worth of at least $19.7 million dollars.
- He owns over 7,500 units of Harrow Health stock worth over $18,125,731.
- Baum has sold HROW stock worth over $219,135 in the last 10 years.
- As the CEO and Director of Harrow Health, he earns a total compensation of $1,377,010.
- Baum is involved in other business ventures and is a founder and board member of several pharmaceutical companies.
Mark Baum Stock Trading History
Mark Baum, the Chief Executive Officer and Director of Harrow Health, has been actively involved in stock trading over the years. His trading history reveals a strategic approach and a deep understanding of the market. Since 2015, Baum has made over 13 trades of Harrow Health stock, showcasing his confidence in the company’s performance.
| Date | Type | Units | Value |
|---|---|---|---|
| November 16, 2023 | Buy | 7,500 | $60,825 |
| April 25, 2021 | Exercise | 850,000 | $7,616,000 |
The most recent trade made by Baum was on November 16, 2023, when he purchased 7,500 units of Harrow Health stock worth $60,825. This transaction reflects his optimism in the company’s future growth. However, his largest trade to date was on April 25, 2021, when he exercised 850,000 units of Harrow Health stock, valued at an impressive $7,616,000.
On average, Mark Baum trades around 85,878 units of Harrow Health stock every 101 days since 2013. This consistent activity demonstrates his commitment to strategic decision-making and his confidence in the company’s long-term prospects.
Mark Baum’s stock trading history exemplifies his expertise in the market and reflects his belief in Harrow Health’s potential for success.
Mark Baum Biography and Career
Mark L. Baum, J.D., serves as the Chief Executive Officer and Director of Harrow Health. He is a highly successful and influential figure in the healthcare industry. With a background as a U.S. securities lawyer, Baum has been instrumental in the restructuring and reorganization of Harrow Health, leading the company to its current status as a highly successful ophthalmic-focused healthcare company.
Prior to his role at Harrow Health, Baum founded and managed TBLF, LLC, a consulting firm and fund manager. His extensive experience in the pharmaceutical industry has also led him to become a founder and board member of several other pharmaceutical companies, including Eton Pharmaceuticals, Inc., Surface Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and subsidiaries Mayfield Pharmaceuticals, Inc., and Radley Pharmaceuticals, Inc.
Baum’s expertise and leadership have played a significant role in the growth and success of Harrow Health. Under his guidance, the company has achieved remarkable milestones, making a significant impact in the ophthalmology outsourcing and pharmaceutical compounding business. With his vast knowledge and experience, Baum continues to contribute to the advancement of the healthcare industry.
Mark Baum’s Career Highlights:
- Chief Executive Officer and Director of Harrow Health
- Founder and Board Member of TBLF, LLC
- Founder and Board Member of Eton Pharmaceuticals, Inc.
- Founder and Board Member of Surface Pharmaceuticals, Inc.
- Founder and Board Member of Melt Pharmaceuticals, Inc.
- Founder and Board Member of Mayfield Pharmaceuticals, Inc. and Radley Pharmaceuticals, Inc. (subsidiaries)
“Mark Baum’s leadership and expertise have been invaluable in driving Harrow Health’s success and growth. His vast experience in the pharmaceutical industry has positioned the company as a leader in ophthalmic healthcare. Baum’s contributions continue to shape the future of the industry.”
Mark Baum Salary and Compensation
As the Chief Executive Officer and Director of Harrow Health, Mark Baum earns a total compensation of $1,377,010. He is the highest-paid executive at the company.
Mark Baum’s salary and compensation reflect his position as a key leader in the organization. His responsibilities as CEO and Director include overseeing the company’s operations, making strategic decisions, and driving its growth and success.
It is worth noting that Mark Baum’s compensation is based on his contributions to Harrow Health and the value he brings to the company. As CEO, he plays a crucial role in driving the company’s performance and achieving its financial goals.
Overall, Mark Baum’s salary and compensation reflect his position as a top executive and his significant impact on the success of Harrow Health.
| Position | Salary | Bonus | Stock Awards | Total Compensation |
|---|---|---|---|---|
| CEO and Director | $1,377,010 | $0 | $0 | $1,377,010 |
Note: The above table represents Mark Baum’s salary and compensation as the CEO and Director of Harrow Health. The total compensation includes salary, bonuses, and stock awards.
Mark Baum Insider Trading at Harrow Health
Insider trading refers to the buying or selling of a company’s stock by individuals who have access to non-public information about the company. Mark Baum, the Chief Executive Officer and Director of Harrow Health, has made several insider trades at the company, providing insights into his investment decisions and sentiment.
Over the last 5 years, insiders at Harrow Health, including Mark Baum, have traded over $1,363,111 worth of Harrow Health stock. These trades involve both buying and selling of shares, indicating Baum’s active involvement in managing his investment portfolio.
“Insider trading can provide valuable information about a company’s prospects and the confidence its executives have in its future,” says Baum.
As of the latest available data, Mark Baum still owns at least 2,022,961 units of Harrow Health stock. This indicates a continued belief in the company’s growth potential and a long-term commitment to its success.
| Date | Type | Shares Traded | Price per Share | Value |
|---|---|---|---|---|
| November 16, 2023 | Buy | 7,500 | $8.11 | $60,825 |
| April 25, 2021 | Exercise | 850,000 | N/A | $7,616,000 |
Mark Baum’s insider trading activities at Harrow Health provide valuable insights for investors, shedding light on his confidence in the company’s future and potential growth.
Mark Baum’s Other Business Ventures
Aside from his role at Harrow Health, Mark Baum is actively involved in several other pharmaceutical companies. Baum is a founder and board member of Eton Pharmaceuticals, Inc., Surface Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and subsidiaries Mayfield Pharmaceuticals, Inc., and Radley Pharmaceuticals, Inc. With his extensive experience and expertise in the industry, Baum plays a significant role in shaping the success and growth of these companies.
Mark Baum’s involvement in multiple pharmaceutical ventures showcases his dedication and commitment to advancing healthcare solutions. These companies work towards developing innovative pharmaceutical products, contributing to the improvement of patient outcomes and addressing unmet medical needs. Baum’s strategic guidance and leadership contribute to the success of these ventures, further solidifying his reputation as a prominent figure in the pharmaceutical industry.
Mark Baum’s active involvement in various pharmaceutical companies demonstrates his commitment to driving innovation and finding solutions to healthcare challenges. His contributions to Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals, and Radley Pharmaceuticals highlight his ability to identify promising opportunities and lead successful ventures within the pharmaceutical sector.
Mark Baum’s diverse business ventures in the pharmaceutical industry exemplify his entrepreneurial spirit and passion for making a positive impact. Through his involvement in these companies, Baum continues to drive innovation, foster collaboration, and contribute to advancements in the field of healthcare.
Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on improving patient outcomes through the development and commercialization of innovative products. With Mark Baum as a founder and board member, Eton Pharmaceuticals is poised for success in bringing valuable medications to the market.
Surface Pharmaceuticals, Inc.
Surface Pharmaceuticals, Inc. is committed to developing novel therapeutics to address critical unmet medical needs. Mark Baum’s role as a founder and board member contributes to the company’s mission of improving patient care and quality of life.
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. focuses on the development and manufacturing of innovative oral thin films for the delivery of pharmaceutical products. With Mark Baum’s involvement, the company aims to revolutionize drug delivery methods and enhance patient convenience and compliance.
Mayfield Pharmaceuticals, Inc.
Mayfield Pharmaceuticals, Inc. is dedicated to discovering and developing breakthrough treatments across various therapeutic areas. Mark Baum’s role as a founder and board member underscores the company’s commitment to advancing healthcare solutions and improving patient outcomes.
Radley Pharmaceuticals, Inc.
Radley Pharmaceuticals, Inc. is a pharmaceutical company focused on the research and development of novel therapeutics. Mark Baum’s contributions as a founder and board member support the company’s mission to address unmet medical needs and drive innovation in the pharmaceutical industry.
Mark Baum’s involvement in these diverse business ventures highlights his profound impact on the pharmaceutical industry, as well as his dedication to advancing healthcare and improving patient outcomes.
Harrow Health Overview
Harrow Health, Inc. is a leading ophthalmic-focused healthcare company that specializes in providing innovative solutions in the ophthalmology sector. The company owns ImprimisRx, a renowned outsourcing and pharmaceutical compounding business that caters specifically to the needs of ophthalmologists. With an unwavering commitment to excellence, Harrow Health strives to provide exceptional products and services that enhance patient care and improve treatment outcomes.
As a pharmaceutical company, Harrow Health not only focuses on its core business but also holds equity interests in other pharmaceutical companies. This strategic diversification allows the company to leverage its expertise and resources to expand its reach in the healthcare industry.
“We believe that every patient deserves access to high-quality, affordable ophthalmic medications and personalized treatment options. Our goal is to revolutionize the ophthalmology sector by introducing innovative solutions that address the unique challenges and needs of healthcare professionals and patients,” said Mark Baum, CEO and Director of Harrow Health.
Harrow Health was previously known as Imprimis Pharmaceuticals, Inc. before rebranding itself as Harrow Health, Inc. in 2018. The company has a strong presence in the ophthalmology field and continues to explore new avenues for growth and expansion.
| Founded | Specialization | Equity Interests |
|---|---|---|
| In 2012 | Ophthalmology | Multiple Pharmaceutical Companies |
Key Executives and Insiders at Harrow Health
As a leading ophthalmic-focused healthcare company, Harrow Health is driven by a strong and capable leadership team. The key executives at Harrow Health play a pivotal role in shaping the company’s strategic direction and driving its success. Let’s take a closer look at the key executives and insiders who contribute to the growth and development of Harrow Health.
Harrow Health Executives
1. Mark Baum – CEO and Director:
Mark Baum serves as the Chief Executive Officer and Director of Harrow Health. With his extensive experience and expertise, Baum has been instrumental in leading the restructuring and reorganization of the company since 2011. His strategic vision and leadership skills have been vital in driving Harrow Health’s growth and success.
2. Andrew Boll – CFO, Corporate Secretary:
Andrew Boll is the Chief Financial Officer and Corporate Secretary of Harrow Health. With his financial acumen and expertise, Boll plays a crucial role in managing the company’s financial operations and ensuring its financial stability. His contributions are integral to Harrow Health’s overall financial performance.
Harrow Health Insiders
Harrow Health insiders are individuals who have a deep understanding of the company and its operations. These insiders contribute to the overall success of the company through their valuable insights and expertise. While there are several directors and independent board members at Harrow Health, it is worth highlighting the following:
1. John Saharek – President of ImprimisRx:
John Saharek serves as the President of ImprimisRx, Harrow Health’s ophthalmology outsourcing and pharmaceutical compounding business. With his extensive knowledge of the ophthalmic industry, Saharek plays a vital role in driving the success of ImprimisRx and ensuring the delivery of high-quality products and services to customers.
Through the collective efforts of these key executives and insiders, Harrow Health continues to thrive as a leading player in the healthcare industry, providing innovative solutions to meet the needs of patients and healthcare professionals alike.
Mark Baum’s Holdings and Ownership Summary
Mark Baum, the Chief Executive Officer and Director of Harrow Health, holds significant stock holdings in multiple companies. His investment portfolio consists of three main stocks: Harrow Health, Eton Pharmaceuticals, and Ideal Power. These holdings provide insights into Baum’s diverse investment strategy and his involvement in the pharmaceutical and energy sectors.
Harrow Health:
As of the latest available data, Baum owns 2,022,961 shares of Harrow Health. This substantial stake demonstrates his confidence in the company’s future prospects and its potential for growth in the ophthalmic healthcare industry. Harrow Health, formerly known as Imprimis Pharmaceuticals, is an established player in the market, owning ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business.
Eton Pharmaceuticals:
Baum also holds 794,745 shares of Eton Pharmaceuticals, Inc., further diversifying his investment portfolio within the pharmaceutical sector. Eton Pharmaceuticals focuses on developing and commercializing innovative drug products that address unmet medical needs. Baum’s ownership in Eton Pharmaceuticals indicates his interest in supporting the advancement of healthcare solutions.
Ideal Power:
In addition to his pharmaceutical investments, Mark Baum holds 2,906 shares of Ideal Power, a company operating in the energy sector. Ideal Power specializes in the development and commercialization of advanced power conversion technologies. Baum’s ownership in Ideal Power highlights his involvement in sustainable energy solutions and his recognition of the importance of the energy industry in driving global innovation.
Mark Baum’s stock holdings in Harrow Health, Eton Pharmaceuticals, and Ideal Power collectively contribute to his estimated net worth of at least $15.2 million. These investments demonstrate his commitment to diverse sectors and his belief in the potential of these companies to deliver long-term value to investors.
| Stock | Number of Shares |
|---|---|
| Harrow Health | 2,022,961 |
| Eton Pharmaceuticals | 794,745 |
| Ideal Power | 2,906 |
Michael Burry and The Big Short
In addition to the fictional character Mark Baum, there is another notable figure associated with “The Big Short” – Michael Burry. Burry’s story became famous for his incredible success in betting against the housing market. The book and film adaptation of “The Big Short” shed light on his remarkable journey.
Michael Burry, an investor with a keen eye for spotting trends, recognized early on the instability in the housing market. He saw the flaws and risks within the mortgage-backed securities that were being widely traded. Burry had the foresight to predict the impending collapse and made a bold move to bet against these securities.
His conviction paid off tremendously when the financial crisis hit. Burry’s investment strategy earned him substantial profits while many others suffered significant losses. His story serves as a reminder of the importance of critical thinking and thorough analysis in the financial world.
The depiction of Michael Burry’s remarkable journey in “The Big Short” provides a captivating insight into the world of finance and the events leading up to the 2008 global financial crisis.
FAQ
How much is Mark Baum worth?
Mark Baum has an estimated net worth of at least $19.7 million dollars as of November 16, 2023.
What is Mark Baum’s stock trading history?
Mark Baum has made over 13 trades of Harrow Health stock since 2015. His most recent trade was buying 7,500 units of HROW stock worth $60,825 on November 16, 2023.
What is Mark Baum’s biography and career?
Mark L. Baum, J.D., serves as the Chief Executive Officer and Director of Harrow Health. He led the restructuring and reorganization of Harrow in 2011 and has been instrumental in its growth since then.
How much is Mark Baum’s salary and compensation?
Mark Baum makes $1,377,010 as the Chief Executive Officer and Director at Harrow Health. He is the highest-paid executive at the company.
Has Mark Baum been involved in insider trading at Harrow Health?
Mark Baum has made several insider trades at Harrow Health, buying and selling stock. Over the last 5 years, insiders at Harrow Health have traded over $1,363,111 worth of Harrow Health stock.
What other business ventures is Mark Baum involved in?
Besides his role at Harrow Health, Mark Baum is a founder and board member of several other pharmaceutical companies, including Eton Pharmaceuticals, Inc., Surface Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and subsidiaries Mayfield Pharmaceuticals, Inc., and Radley Pharmaceuticals, Inc.
Can you provide an overview of Harrow Health?
Harrow Health, Inc. is an ophthalmic-focused healthcare company that owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. It also holds equity interests in other pharmaceutical companies.
Who are the key executives and insiders at Harrow Health?
The key executives at Harrow Health include Mark Baum (CEO and Director), Andrew Boll (CFO, Corporate Secretary), and John Saharek (President of ImprimisRx). There are several other directors and independent board members at the company.
What stocks does Mark Baum currently own?
Mark Baum currently owns a total of 3 stocks, including Harrow Health, Eton Pharmaceuticals, and Ideal Power.
What is the connection between Michael Burry and The Big Short?
While Mark Baum is a fictional character based on real person Steve Eisman, it’s worth mentioning Michael Burry in relation to The Big Short. Burry is another investor who made a fortune by betting against the housing market. His story was famously depicted in the book and film adaptation of The Big Short.
Create your very own Auto Publish News/Blog Site and Earn Passive Income in Just 4 Easy Steps
